Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKuş, Gökhan
dc.contributor.authorÖzkurt, Mete
dc.contributor.authorÖztopçu Vatan, Pınar
dc.contributor.authorErkasap, Nilüfer
dc.contributor.authorUyar, Ruhi
dc.contributor.authorKabadere, Selda
dc.date.accessioned2019-10-18T19:26:34Z
dc.date.available2019-10-18T19:26:34Z
dc.date.issued2018
dc.identifier.issn1300-0152
dc.identifier.issn1303-6092
dc.identifier.urihttps://dx.doi.org/10.3906/biy-1712-46
dc.identifier.urihttps://hdl.handle.net/11421/11534
dc.descriptionWOS: 000435091000007en_US
dc.descriptionPubMed ID: 30814888en_US
dc.description.abstractInhibiting ceramidase activity in cancer cells has been identified as a promising target for cancer therapy in recent studies. Thus, we examined the possible role of ceranib-2, a novel ceramidase inhibitor, on growth and apoptotic mechanisms of the human normal glia cell line (HNA), human glioma cell lines (T-98G and U-87MG), and a rat glioma cell line (C6). We also compared the results with the effects of C2 ceramide and cisplatin. We determined the in vitro survival rate with MTT assay, apoptosis with flow cytometry, gene expressions with qRT-PCR, and statistical significance by one-way analysis of variance together with Tukey's test. Calculated from MTT outcomes, the inhibitory ranking was as follows: T-98G > U-87MG > C6 > HNA. Ceranib-2 had the most growth-suppressive activity on human T-98G cells with an IC50 of 7 mu M for 24 h and 0.9 mu M for 48 h. Only the 25 mu M dose of ceranib-2 induced apoptosis of human T-98G and U-87MG cells after 24 h of treatment; however, it increased apoptosis of C6 cells dose- and time-dependently. Ceranib-2 increased the cytochrome c gene expression level during 24 h in T-98G cells. Ceranib-2 had cytotoxic and apoptotic effects on glioma cells but the cytotoxic effect was weaker on normal glia cells. 'Ibis cytotoxicity was stronger than that of C2 ceramide and cisplatin.en_US
dc.description.sponsorshipEskisehir Osmangazi University Scientific Research Projects Committee [2012/11032]en_US
dc.description.sponsorshipThis study was presented at the Joint Meeting of the Federation of European Physiological Societies and the Baltic Physiological Societies (FEPS), Kaunas, Lithuania on 26-29 August 2015, and in National Application Congress of Biological Sciences, 26-29 December 2016, Konya, Turkey. This study was funded by the Eskisehir Osmangazi University Scientific Research Projects Committee (grant number 2012/11032).en_US
dc.language.isoengen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.isversionof10.3906/biy-1712-46en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCeranib-2en_US
dc.subjectC2 Ceramideen_US
dc.subjectCisplatinen_US
dc.subjectApoptosisen_US
dc.subjectGliomaen_US
dc.titleComparison of a ceramidase inhibitor (ceranib-2) with C2 ceramide and cisplatin on cytotoxicity and apoptosis of glioma cellsen_US
dc.typearticleen_US
dc.relation.journalTurkish Journal of Biologyen_US
dc.contributor.departmentAnadolu Üniversitesi, Açıköğretim Fakültesi, Sağlık Kurumları İşletmeciliğien_US
dc.identifier.volume42en_US
dc.identifier.issue3en_US
dc.identifier.startpage259en_US
dc.identifier.endpage265en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorKuş, Gökhan


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster